top of page

®

Cysto One PAP  

The Cysto One PAP is a molecular test to screen and diagnose low and high grade urinary bladder malignancies as well as urinary tract infections and sexually transmitted diseases.  

Cysto One PAP  Panel Menu

Performance: 100% sensitivity and 99.8% specificity 
Sample Type: Voided Urine

Methodology: Real-Time PCR

Run time: 24 hours 

UTI Molecular Assay Panel

STI Assay Molecular Panel

Antimicrobial Resistance  Genes

Acinetobacter baumannii

Actinotignum schaalii

Aerococcus urinae 
Alloscardovia omnicolens

Candida albicans 
Candida auris
Citrobacter freundii 
Citrobacter koseri 
Coagulase negative staphylococci  

Corynebacterium riegelii

Enterobacter aerogenes  

Enterobacter cloacae complex

Enterococcus faecalis

Enterococcus faecium 
Erratia marcescens 
Escherichia coli 

 

Gardnerella vaginalis 
Klebsiella oxytoca 

Klebsiella pneumoniae 

Morganella morgani i 

 

Pantoea sp 

Proteus mirabilis 

Proteus vulgaris 

 

Providencia stuartii 

Pseudomonas aeruginosa

 

Staphylococcus aureus

 

Staphylococcus saprophyticus

 

Streptococcus agalactiae (group B)

 

Streptococcus dysgalactiae 

 

Candida glabrata 

 

Candida parapsilosis

 

Chlamydia Trachomatis

 

Herpes / HSV1 

 

Herpes / HSV2  

 

Mobiluncus curtisii

 

Mycoplasma genitaliumm

 

 Mycoplasma hominis  

 

Neisseria Gonorrhoeae

 

Treponema pallidum (Syphillus)

 

Trichomonas Vaginalis

 

Ureaplasma urealyticum 

aph(3')-VI, aph(3')-Vla, aph(3')-Vib

 

aac(6')-b-cr

 

mcr-1

 

VanA/VanB/VanC

 

ErmA/ErmB/ErmC/MefA 

 

Cfr gene

nimA

nimB

nimC

nimD

nimE

nimH

QnrA/QnrS

Sul1/Sul2

TetS

TetB/TetM

DftA1/DfrAS

CTX-M

KPC

SHV

GES

IMP

VIM

NDM

CMY-1/MOX

ACT

FOX

MIR

CMY, LAT

ACC

MecA

OXA-33/OXA-34/ORA 51/OKA-48

AdobeStock_286066389_edited_edited_edite

Boost effectiveness of patient testing

 

Urinary Tract Infections (UTIs) account for 83 million doctor visits, 1 million emergency department (ED) visits, and 100,000 hospitalizations annually with an estimated cost of $1 billion annually in the US. Annually, there are over 84,000 new diagnoses of bladder cancer in the U.S.A and 430,000 globally, making it the fourth most prevalent malignancy in men and the fifth most prevalent in woman. Prognosis and mortality is strongly correlated with cancer staging at the time of diagnosis.

Why Cysto One PAP? 

 

The Cysto One PAP screens for presence of Cytokeratin17. Keratin17 is an immunobiomarker which is

involved in the replication cycle of malignant cells. Presence of  keratin 17 is a highly specific immunobiomarker for presence of urinary bladder malignancy. In addition Cysto One PAP is designed to test for a host of other infectious urological conditions.

Screenshot 2023-03-27 at 11.47.27 AM.png
Screenshot 2023-03-27 at 11.47.36 AM.png

Ultra Solutions

Molecular Reporting 

No more, complicated, redundant paperwork or late reports. As a

service oriented, independent and fully certified provider, PCG

Molecular can streamline the process and put the focus where it

belongs– on you, the client. Our policy of speedy and efficient

turnaround for our clients means fast access to the information you

need via all forms of electronic transmittal and increased efficiency

in the day to day operations of your own practice.

bottom of page
src="https://www.googletagmanager.com/gtag/js?id=G-RMJ50BG0P4">